Detalles de la búsqueda
1.
Exosome Analysis in Prostate Cancer: How They Can Improve Biomarkers' Performance.
Curr Issues Mol Biol
; 45(7): 6085-6096, 2023 Jul 21.
Artículo
en Inglés
| MEDLINE | ID: mdl-37504300
2.
Prognostic Value of Albumin to Globulin Ratio in Non-Metastatic and Metastatic Prostate Cancer Patients: A Meta-Analysis and Systematic Review.
Int J Mol Sci
; 23(19)2022 Sep 29.
Artículo
en Inglés
| MEDLINE | ID: mdl-36232828
3.
How the Analysis of the Pathogenetic Variants of DDR Genes Will Change the Management of Prostate Cancer Patients.
Int J Mol Sci
; 24(1)2022 Dec 30.
Artículo
en Inglés
| MEDLINE | ID: mdl-36614122
4.
A biofeedback-guided programme or pelvic floor muscle electric stimulation can improve early recovery of urinary continence after radical prostatectomy: A meta-analysis and systematic review.
Int J Clin Pract
; 75(10): e14208, 2021 Oct.
Artículo
en Inglés
| MEDLINE | ID: mdl-33811418
5.
Intermittent Versus Continuous Androgen Deprivation Therapy for Biochemical Progression After Primary Therapy in Hormone-Sensitive Nonmetastatic Prostate Cancer: Comparative Analysis in Terms of CRPC-M0 Progression.
Clin Genitourin Cancer
; 22(2): 74-83, 2024 04.
Artículo
en Inglés
| MEDLINE | ID: mdl-37758559
6.
Prognostic role of platelet-to-lymphocyte ratio and neutrophil-to-lymphocyte ratio in patients with non-metastatic and metastatic prostate cancer: A meta-analysis and systematic review.
Asian J Urol
; 11(2): 191-207, 2024 Apr.
Artículo
en Inglés
| MEDLINE | ID: mdl-38680577
7.
Regenerative Medicine-Based Treatment of Stress Urinary Incontinence with Mesenchymal Stem Cells: A Systematic Review and Meta-analysis.
Curr Stem Cell Res Ther
; 18(3): 429-437, 2023.
Artículo
en Inglés
| MEDLINE | ID: mdl-35713128
8.
Is It Time to Anticipate the Use of PARP Inhibition in Prostate Cancer Patients?
Curr Oncol
; 30(9): 8054-8067, 2023 08 30.
Artículo
en Inglés
| MEDLINE | ID: mdl-37754499
9.
Translation and validation of the Italian version of the Wisconsin Stone Quality of Life Questionnaire (I-WISQOL) for assessing quality of life in patients with urolithiasis.
Minerva Urol Nephrol
; 75(4): 501-507, 2023 Aug.
Artículo
en Inglés
| MEDLINE | ID: mdl-37067185
10.
Comparison of Different Invasive Devices for the Treatment of Urinary Incontinence after Radical Prostatectomy.
Adv Urol
; 2022: 8736249, 2022.
Artículo
en Inglés
| MEDLINE | ID: mdl-35774194
11.
Which factors can influence post-operative renal function preservation after nephron-sparing surgery for kidney cancer: a critical review.
Cent European J Urol
; 75(1): 14-27, 2022.
Artículo
en Inglés
| MEDLINE | ID: mdl-35591956
12.
Comparative Prospective and Longitudinal Analysis on the Platelet-to-Lymphocyte, Neutrophil-to-Lymphocyte, and Albumin-to-Globulin Ratio in Patients with Non-Metastatic and Metastatic Prostate Cancer.
Curr Oncol
; 29(12): 9474-9500, 2022 12 03.
Artículo
en Inglés
| MEDLINE | ID: mdl-36547159
13.
How to Predict Outcomes from a Biofeedback and Pelvic Floor Muscle Electric Stimulation Program in Patients with Urinary Incontinence after Radical Prostatectomy.
J Clin Med
; 11(1)2021 Dec 27.
Artículo
en Inglés
| MEDLINE | ID: mdl-35011866
14.
Influence of operative time and blood loss on surgical margins and functional outcomes for laparoscopic versus robotic-assisted radical prostatectomy: a prospective analysis.
Cent European J Urol
; 74(4): 503-515, 2021.
Artículo
en Inglés
| MEDLINE | ID: mdl-35083069
15.
Early recovery of urinary continence after radical prostatectomy using early pelvic floor electrical stimulation and biofeedback associated treatment.
J Urol
; 181(4): 1788-93, 2009 Apr.
Artículo
en Inglés
| MEDLINE | ID: mdl-19233390
16.
Prostate growth and inflammation.
J Steroid Biochem Mol Biol
; 108(3-5): 254-60, 2008 Feb.
Artículo
en Inglés
| MEDLINE | ID: mdl-17935971
17.
Quantitative analysis of urinary incontinence after prostatectomy: lack of standardization in trials.
Minerva Urol Nephrol
; 74(3): 249-251, 2022 06.
Artículo
en Inglés
| MEDLINE | ID: mdl-35607781
18.
Comment on: "Androgen receptor axis-targeted agents for non-metastatic castration-resistant prostate cancer impact on overall survival and safety profile: an updated systematic review and meta-analysis".
Minerva Urol Nephrol
; 74(3): 360-362, 2022 06.
Artículo
en Inglés
| MEDLINE | ID: mdl-35607782
19.
DDR genes analysis and PARP-inhibitors therapy as tailored management in metastatic prostate cancer: achieved answers, open questions and future perspectives.
Minerva Urol Nephrol
; 74(6): 649-652, 2022 12.
Artículo
en Inglés
| MEDLINE | ID: mdl-36629806
20.
Prognostic role of platelet-to-lymphocyte ratio and neutrophil-to-lymphocyte ratio in patients with metastatic castration resistant prostate cancer treated with abiraterone or enzalutamide.
Minerva Urol Nephrol
; 73(6): 863-865, 2021 Dec.
Artículo
en Inglés
| MEDLINE | ID: mdl-35144373